Update on Arlo-Cel, a GPRC5D CAR-T, in RRMM | Ciara Freeman, MD, PhD

My name is Doctor Ciara Freeman, and I am from the Moffitt Cancer Center in Tampa, Florida.

And I'm here at the annual Society of Hematology meeting in Orlando, Florida, and I'm presenting an abstract of a trials-in-progress on behalf of all my co-investigators across the trial on QUINTESSENTIAL.

So the trial is involving patients who have relapsed refractory myeloma, who are, a new term is called, quad-exposed.

So they have seen not only are three big classes of drugs—immunomodulators, proteasome inhibitors, and monoclonal antibodies directed to CD38—but they've also previously seen BCMA-directed therapies.

So now the big four have all been exhausted.

And these patients are relapsing after all of those major drug choices. These are the patients that were uniquely enrolling into this CAR-T cell trial.

The trial itself is open across over 47 sites in the USA, Japan, and Canada.

Patients are going to be treated universally.

This is a phase two trial with or alrocabtagene autoleucel, otherwise known as Arlo-cel.

The target of this CAR-T cell therapy is GPRC5D.

So that's the same target that is used by talquetamab, which is a bispecific antibody.

That same target is also expressed on myeloma cells, but can also be expressed on taste, salivary glands, skin, and nails, and can cause some of the side effects that we see from talquetamab.

Equally, there's some concern about whether it's expressed on the cerebellum and whether that might be an issue or not.

So far, the phase one data looks very promising, with high overall response rates.

That's already been reported out.

And this phase two trial is evaluating Arlo-cel in patients who are universally quad-exposed.

So this is a very difficult-to-treat patient population.

They've seen all our major classes of drugs.

So it offers those kinds of patients a new option in the trial landscape.

And it's going to be very exciting to see what the results of this trial look like.

If my videos have helped you in any way, and you're able to, please consider making a donation to help us continue this important work.

Your gift will go three times as far when we reach $500,000 by the end of the year.

Every contribution, big or small, makes a difference, and we're deeply grateful for your support.